关于变更注册资本暨修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海澳华内镜股份有限公司 证券代码：688212 证券简称：澳华内镜 公告编号：2024-028 上海澳华内镜股份有限公司（以下简称"公司"）于 2024 年 6 月 25 日召开 的第二届董事会第十二次会议，审议通过了《关于变更注册资本暨修订<公司章 程>的议案》，现将相关事项公告如下： 一、变更公司注册资本的基本情况 公司 2022 年限制性股票激励计划首次授予部分第二个归属期归属事项已于 2024 年 5 月 14 日完成股份登记工作，归属股票数量 554,250 股，并于 2024 年 5 月 20 日上市流通。本次限制性股票归属后，公司股本总数由 134,033,000 股 增加至 134,587,250 股，注册资本由人民币 134,033,000 元增加至人民币 134,587,250 元。 二、修订公司章程的情况 根据上述变更事项，公司拟对《公司章程》进行修订，具体修订内容如下： | 修订前 | | 修订后 | | | ...

证券代码：688212 证券简称：澳华内镜 公告编号：2024-027 上海澳华内镜股份有限公司 关于增加2024年度公司及子公司申请授信额度的公告 以上授信额度不等于公司的实际融资金额，预计发生金额在总授信额度内，以公司 及全资子公司与银行等金融机构实际发生的金额为准。授信期限内，授信额度可循环使 用。 本次增加申请授信额度事项在公司董事会权限范围内，无需提交股东大会审议。公 司董事会授权公司经营管理层根据公司实际经营情况的需要，在上述综合授信额度内， 全权办理公司向银行等金融机构申请授信相关的具体事项。 特此公告。 公司于2024年4月8日召开第二届董事会第十次会议及第二届监事会第九次会议，审 议通过了《关于2024年度公司及子公司申请综合授信额度及提供担保的议案》。同意公 司及全资子公司2024年度向银行等金融机构申请不超过人民币12,000万元的综合授信额 度。具体内容详见公司于2024年4月10日在上海证券交易所网站（www.sse.com.cn）披露 的《上海澳华内镜股份有限公司关于公司及子公司申请综合授信额度并提供担保的公 告》（公告编号：2024-010）。 截至本公告披露日，公司及子公司已实 ...

Product Development and Feedback - AQ-300 product received positive clinical feedback, with high praise for image clarity, color accuracy, and operability [1] - The company continuously optimizes product performance based on clinical feedback to provide precise and reliable operation experiences [2] Market and Industry Trends - The soft endoscopy market is driven by increasing clinical diagnostic needs and rising early cancer screening rates [2] - Hospital demand for new and replacement soft endoscopy equipment is growing due to increased diagnostic requirements [2] Financial and Operational Strategies - The company conducted two rounds of equity incentives in 2022 and 2023, leading to increased share-based payment expenses in 2024 [2] - The sales team and distributors are stable and experienced, actively working to explore market potential through refined marketing management [2] Academic and Industry Engagement - The company actively participates in industry conferences and engages with experts to discuss innovation, clinical practices, and technological developments [3] - Successful events like the "Aohua Cup" CBI National Case Competition and hands-on training sessions have provided learning opportunities and showcased product advantages [3]

Investment Rating - The report maintains a "Buy" rating for the company [21][22]. Core Insights - The company has opened a second growth curve in overseas markets, with products entering developed markets such as Germany, the UK, and South Korea. The marketing strategy in Asia is aggressive, while in Europe, the company is expanding brand influence and promoting mid-to-low-end models [3][4]. - The recent stock incentive plan reflects management's confidence, with performance targets set for 2024-2026, aiming for revenues of no less than 0.99 billion, 1.4 billion, and 2 billion, and net profits of no less than 0.12 billion, 0.18 billion, and 0.27 billion respectively [4][19]. - The company reported a revenue growth of over 50% in 2023, driven by the rapid market penetration of the new AQ-300 product. By the end of 2023, the number of installations in tertiary hospitals reached 73, with 96 main units and 316 endoscopes installed [19][18]. - The company is deepening its R&D investments, with 26% of Q1 2024 revenue allocated to R&D, enhancing product quality and gaining clinical recognition across various medical departments [20][19]. Financial Summary - In 2023, the company achieved a revenue of 678 million, a year-on-year increase of 52.29%, and a net profit of approximately 58 million, up 167.04%. The first quarter of 2024 saw revenues of 169 million, a 34.91% increase year-on-year, with a net profit of 2.76 million, down 83.32% [18][19]. - The projected net profits for 2024-2026 are estimated at 1.23 billion, 1.82 billion, and 2.69 billion respectively, with corresponding PE ratios of 54, 37, and 25 times [21][22].

Financial Data and Key Metrics Changes - The company set a revenue target of 990 million for the year, corresponding to a nearly 50% growth rate [1] - In 2023, the revenue reached 678 million, achieving the stock incentive target of 50% growth and a profit of 120 million after basic share payments [5] - The revenue from the AQ-300 model accounted for over half of the total revenue in 2023 [5] - The company expects revenue targets of 1.4 billion for next year and 2 billion for the year after [7] Business Line Data and Key Metrics Changes - The number of installations in tertiary hospitals for mid-to-high-end models increased from 25 in 2022 to 73 in 2023 [5] - The total number of units installed in 2023 was 96, compared to 26 in 2022, indicating rapid growth [5] - The company aims to exceed 200 installations in tertiary hospitals in 2024 [9] Market Data and Key Metrics Changes - The company’s market share is expected to exceed 10% by the end of the year [1] - The overseas market consists of approximately 60% in Europe and the rest in cost-sensitive markets like Latin America, India, and Russia [9] - The company noted a 12% decline in the market share of a competitor in China, indicating the impact of anti-corruption measures [9] Company Strategy and Development Direction - The company plans to maintain a research and development expense ratio of over 20% [9] - Future product lines include the AQ-400 and a soft endoscope robot targeting ERCP procedures, addressing significant unmet market needs [9][24] - The company is focusing on expanding its market share in the soft endoscope segment, which currently stands at a low percentage [24] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the revenue targets, citing strong product performance and market demand [7] - The company anticipates a recovery in academic activities and public bidding in the context of normalized anti-corruption measures [21] - The management highlighted the importance of maintaining a responsive maintenance network for medical devices [20] Other Important Information - The company is actively recruiting for its sales and R&D teams, with a focus on maintaining efficiency rather than significant headcount increases [10] - The company is exploring partnerships with local distributors in Europe to enhance its service capabilities [20] Q&A Session Summary Question: Is the AQ-300's performance in the first half of the year in line with annual expectations? - Management indicated that the performance is generally in line with expectations, with a focus on year-over-year comparisons rather than quarter-over-quarter [2] Question: What are the revenue guidance and expectations for the next few years? - The company provided revenue targets of 990 million for 2023, 1.4 billion for 2024, and 2 billion for 2025, reflecting strong growth confidence [7] Question: What is the company's strategy for overseas market expansion? - The company is focusing on Europe for high-end products and cost-sensitive markets through distributors for faster growth [19][17] Question: How does the company plan to address the impact of anti-corruption measures? - Management noted that while there are challenges, the company’s low market share allows for continued growth despite industry-wide impacts [21] Question: What is the expected sales expense ratio for 2024/2025? - The company expects the sales expense ratio to stabilize as efficiency improves, with a focus on managing personnel costs [27]

重要内容提示： 现金分红总额调整情况：维持每10股派发现金红利人民币3.00元（含 税）不变，现金分红总额由40,209,900.00元（含税）调整为40,376,175.00元 （含税）。 本次调整原因：上海澳华内镜股份有限公司（以下简称"公司"）因 2022年限制性股票激励计划首次授予部分第二个归属期归属，新增股份554,250 股。公司于2024年5月14日在中国证券登记结算有限责任公司上海分公司完成新 增股份的登记工作，公司总股本由134,033,000股增加为134,587,250股。公司 拟维持每股分配比例不变，对公司2023年度利润分配总额进行相应调整。 证券代码：688212 证券简称：澳华内镜 公告编号：2024-023 上海澳华内镜股份有限公司 关于调整2023年度利润分配总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、调整后利润分配方案 公司于2024年5月14日完成了2022年限制性股票激励计划首次授予部分第二 个 归 属 期 归 属 的 股 份 登 记 工 作 ， 新 增 股 份 ...

欢迎各位投资者参加华安医药联合洛言中举办的夏季现场策略会本场是上市公司奥华内定的交流我们很荣幸的邀请到公司的IR马总和我们一起交流今天交流主要分为两个部分第一部分就是公司的介绍第二部分我们进入QA环节首先有请马总跟我们 用15分钟左右的时间对公司上半年的一个基因情况最新的一个进展做一个讲解吧那这边时间先交给马总马总您这边可以听到吗这边好像您好像在静音不好意思 是这样的我们就是因为我们最近也最新的草包也已经发布我也先给大家再回顾一下过去的我们的几个成绩那么之后呢我们也再把今年的相对应的几个指引或者目标也给大家再同步一下首先是过去的2003年也是对我们公司也是比较重要的一年因为这是 AQ322年底上市以来相当于经历了一个第一个完整的年那么这一年我们的收入是6.78亿相对于我们的股成绩的目标50%增长以及6.6亿的收入目标其实完全达到了然后对应的T2股份之后的利润也达到了目标 去年相对来说是一个完成比较好的一年那么拆分来看的话去年我们的AQ300这个批评的收入占比应该是超过了整体的一半另外呢就是我们能够看到AQ300在这个整体的这个三级在我们公司的这个三级医院的装机上还是做了很大的贡献那么我们财报里也披露了23年全 ...

Company and Industry Summary Company Introduction - The document begins with an introduction to the company, setting the stage for the subsequent discussion on its performance and developments in the first half of the year [1] Key Points from the Q&A Session - The CEO, referred to as Mr. Ma, is expected to provide a detailed explanation of the company's operational status and recent progress over the past six months, with a presentation time of approximately 15 minutes [1]

证券代码：688212 证券简称：澳华内镜 公告编号：2024-022 上海澳华内镜股份有限公司 2022 年限制性股票激励计划首次授予部分 第二个归属期归属结果暨股份上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 554,250 股。 本次股票上市流通总数为 554,250 股。 本次归属股票上市流通日期为 2024 年 5 月 20 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，上海澳华内镜股份有限公司（以下简称 "公司"）于 2024 年 5 月 14 日收到中国证券登记结算有限责任公司上海分公司 出具的《证券变更登记证明》，公司已完成 2022 年限制性股票激励计划（以下简 称"本次激励计划"）首次授予部分第二个归属期的股份登记工作。现将有关情 况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2022 年 1 月 17 日，公司召开第一届董事 ...

Group 1: Financial Performance - In Q1 2024, the company's revenue reached 169 million CNY, representing a year-on-year growth of 34.91% [1] - The net profit attributable to shareholders was 2.76 million CNY, a decrease of 83.32% year-on-year [1] - After excluding the impact of share-based payments, the net profit attributable to shareholders was 24.56 million CNY, reflecting a growth rate of 24.15% compared to the same period last year [1] Group 2: Product Development and Market Strategy - The AQ-300 product was launched at the end of 2022 and has undergone market promotion and performance upgrades in 2023, following an S-curve adoption pattern [2] - The company has obtained EU certification for the AQ-300 product and is actively participating in industry conferences to enhance market presence [2] - Future strategies include expanding the AQ-300 series with more models and enhancing brand recognition through academic exchanges and training sessions [2] Group 3: Market Expansion and Challenges - Europe is a key area for the company's overseas business, with ongoing efforts to penetrate cost-effective markets that still have unmet demand for soft endoscopes [2] - The company aims to focus on technological innovation and brand building in the soft endoscope sector, where domestic brands currently hold a low market share [3] - Increasing the penetration rate of gastrointestinal endoscopies in grassroots healthcare requires collaborative efforts, including government support, training systems, and public health awareness campaigns [3]